Clinical trial
Cellular and Molecular Events During Treatment of Actinic Keratosis With…
NCT00335179 · Graceway Pharmaceuticals, LLC, Industry · Completed
Key facts
| NCT number | NCT00335179 |
|---|---|
| Title | Cellular and Molecular Events During Treatment of Actinic Keratosis With Imiquimod 5% Cream |
| Official title | Double-Blind, Vehicle-Controlled Study to Evaluate Cellular and Molecular Events During Four Weeks of Treatment for Actinic Keratosis With Aldara (Imiquimod) Cream, 5% |
| Lead sponsor | Graceway Pharmaceuticals, LLC, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Actinic Keratosis |
| Intervention type | Drug |
| Interventions | Aldara (imiquimod 5% cream), Vehicle cream |
| Enrollment | 17 |
| Start date | Jan 1, 2003 |
| Primary completion | Jul 1, 2003 |
| Completion | Jul 1, 2003 |
| First posted | Jun 9, 2006 |
| Last update posted | Jul 23, 2010 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: